Genentech Recalls Prescription Evrysdi (risdiplam) Due to the Product Not Meeting Child-Resistant Packaging Requirements

Genentech of South San Francisco, Calif. recalled 14,000 bottles of the prescription drug Evrysdi (risdiplam).

The bottles can leak due to a fit issue between the press-in bottle adapter and bottleneck. If the bottle is leaking, there is a risk of drug exposure by contact with skin or eyes.

This poses a risk of poisoning if the contents are swallowed by toddlers.

This recall involves bottles of the prescription drug Evrysdi, a prescription medicine that is used to treat spinal muscular atrophy (SMA) in adults and children 2 months of age and older.

The firm has received 26 reports of leaking bottles.

The medication was manufactured in Switzerland and was sold at select specialty pharmacies nationwide as a prescribed medicine.

In response to this, Genentech notified purchasers about the recall. The company urges consumers to immediately store the product in a safe location that is out of reach of children.

The company urges customers to also contact them for a free child-resistant replacement camp.

There have been no reported incidents to date.


© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.